Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660726 | 0.90 | L3MBTL1 (0.46) | NPC1RAB9AL3MBTL1PKMSMN1; SMN2 | |
| SCHEMBL666743 | 0.89 | NPC1 (0.40) | NPC1RAB9AL3MBTL1PKMSMN1; SMN2 | |
| SCHEMBL661735 | 0.86 | PPARG (0.44) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL666742 | 0.85 | PPARG (0.39) | NPC1RAB9AL3MBTL1PKMSMN1; SMN2 | |
| SCHEMBL661833 | 0.82 | APLNR (0.35) | HRH3LMNAMAPK1 | |
| SCHEMBL667884 | 0.81 | TP53 (0.34) | SMN1; SMN2HRH3KCNH2CCR2CCR5 | |
| SCHEMBL665635 | 0.80 | PPARD (0.36) | HRH3KCNH2LMNAMAPK1 | |
| SCHEMBL660776 | 0.80 | CACNA2D1 (0.40) | NPC1RAB9APKMSMN1; SMN2HRH3 | |
| SCHEMBL661745 | 0.80 | PPARG (0.45) | — | |
| SCHEMBL671035 | 0.79 | KDM4E (0.38) | SMN1; SMN2POLBCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | PPARA, PPARG, PPARD | NPC1 1827/4885RAB9A 845/4885L3MBTL1 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.